11-25-2008: Invitrogen Corporation and Applied Biosystems Inc. announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and is traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008.
“This is an exciting time in the history of Invitrogen and Applied Biosystems,” said Greg Lucier, Chairman and Chief Executive Officer of Life Technologies. “By combining these two highly respected brands, we are not only creating a stronger company, but an industry thought leader, uniquely positioned to help our customers accelerate and drive new discoveries and commercial applications.
Preliminary results of elections made by Applied Biosystems stockholders regarding their preferences as to the form of merger consideration were announced on November 20, 2008. The majority of Applied Biosystems stockholders elected to receive their consideration in the form of all cash. As a result, those stockholders who have elected to receive the cash consideration will receive slightly more cash and slightly fewer shares than they would have received if they had elected the mixed consideration. The company expects to have final election results and pro-rated disbursement figures determined by November 28, 2008, at which time the company will make an announcement with such figures. Disbursements of proceeds are expected to be made no later than the first week of December.
QIAGEN and Applied Biosystems Settle all Disputes over Real-Time PCR Thermal Cycler Patents
Corbett, QIAGEN, ltf Labortechnik GmbH & Co. KG, and Applied Biosystems, LLC, part of Life Technologies Corporation announced a settlement of their disputes concerning infringement by Corbett’s Rotor-Gene_TM Real-Time PCR-Cyclers and Applied Biosystems’ Real-Time Thermal Cycler Instrument ... more
Invitrogen and Applied Biosystems Complete Merger
Invitrogen Corporation and Applied Biosystems Inc. announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and is traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008. “Thi ... more
Drug toxicity is a leading cause of pre-clinical drug failures. The US Food and Drug Administration (FDA) and other regulatory organisations have called upon the pharmaceutical industry to develop more effective tools to help avoid these costly failures, reduce the number of failed compound ... more
Invitrogen and Applied Biosystems Complete Merger
Invitrogen Corporation and Applied Biosystems Inc. announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and is traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008. “Thi ... more
Invitrogen Corporation Announces Strategic Collaboration with Tecan
Invitrogen Corporation and Tecan are entering into a collaboration agreement to validate the compatibility of Invitrogen's reagents with Tecan's microplate detection instruments. Invitrogen's drug discovery products will be validated on selected Tecan microplate readers and instruments, st ... more
Invitrogen, Agilent Technologies Settle Multiple Patent Litigations
Invitrogen Corporation (IVGN) and Agilent Technologies have jointly announced a confidential settlement of multiple patent litigations pending between the two companies. The settlement resolves three patent infringement lawsuits between Invitrogen and Stratagene Inc. Agilent acquired Strata ... more
BAC BV collaborates with Life Technologies to provide new HPLC affinity columns
BAC BV has announced a strategic collaboration with Life Technologies to bring the wide range of BAC’s CaptureSelect® affinity ligand specificities to Life Technologies’ POROS® chromatography media and pre-packed HPLC columns. The collaboration will create a range of ready-to-use HPLC col ... more
Life Technologies to Sell Mass Spectrometry Business to Danaher for $450 Million in Cash
Life Technologies Corporation announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies’ joint ... more
QIAGEN and Applied Biosystems Settle all Disputes over Real-Time PCR Thermal Cycler Patents
Corbett, QIAGEN, ltf Labortechnik GmbH & Co. KG, and Applied Biosystems, LLC, part of Life Technologies Corporation announced a settlement of their disputes concerning infringement by Corbett’s Rotor-Gene_TM Real-Time PCR-Cyclers and Applied Biosystems’ Real-Time Thermal Cycler Instrument ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
